NLS Pharmaceutics and Kadimastem Complete Merger to Form NewcelX Ltd

October 30, 2025

Swiss-based NLS Pharmaceutics Ltd. merged with clinical-stage cell therapy company Kadimastem Ltd. to create a combined Nasdaq-listed biotechnology company named NewcelX Ltd. The merger closed effective October 30, 2025, with the new company beginning trading on the Nasdaq Capital Market on October 31, 2025 under ticker “NCEL.”

Buyers
NewcelX Ltd., NLS Pharmaceutics Ltd., Kadimastem Ltd.
Targets
NLS Pharmaceutics Ltd., Kadimastem Ltd.
Industry
Biotechnology
Location
Switzerland
Transaction Type
Buyout

Explore More

Related articles

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.

Find buyers like these →